# Neonatal Jaundice

Manage neonatal jaundice with age-specific bilirubin assessment, prompt identification of hemolysis and other high-risk patterns, guideline-based phototherapy, and urgent escalation for bilirubin encephalopathy or exchange-level hyperbilirubinemia.

**Clinical question:** How should clinicians evaluate, treat, and safely follow neonatal jaundice in infants at risk for severe hyperbilirubinemia?

Updated: 2026-08-24T16:20:25.945267+00:00

## What matters in practice
- Use total serum bilirubin (TSB), postnatal age, gestational age, and neurotoxicity risk factors to determine phototherapy, escalation, exchange transfusion, discharge, and readmission decisions. [1][22]
- Jaundice in the first 24 hours, gestational age 35–36 weeks, bruising or cephalohematoma, prior sibling requiring phototherapy, and suspected hemolysis identify infants requiring closer bilirubin surveillance. [3]
- Obtain serum bilirubin and evaluate for underlying disease in significant hyperbilirubinemia; include blood group testing, direct antiglobulin testing, complete blood count, and G6PD testing when severe disease or hemolysis is suspected. [17][21]
- Begin intensive phototherapy at the applicable age- and gestation-specific treatment threshold; inability to lower TSB or ongoing hemolysis requires repeated reassessment and preparation for escalation. [1][17]
- Treat bilirubin levels at the exchange threshold urgently, unless the level falls below that threshold while exchange transfusion is being prepared; clinical acute bilirubin encephalopathy independently signals high risk. [17]
- Plan postdischarge follow-up around the predischarge bilirubin result, age at discharge, and risk trajectory; infants discharged before 24 hours require review within 24 hours with immediate access to TcB or TSB measurement. [21]

## Identify infants needing urgent bilirubin-directed escalation

Separate routine surveillance from potential bilirubin neurotoxicity at the first assessment.

Obtain a TSB when jaundice is clinically significant, when TcB approaches a treatment threshold, or when treatment decisions are being considered. TSB is the key parameter for starting, stopping, or restarting phototherapy; determining exchange transfusion need; and making discharge or readmission decisions. Interpret every value by postnatal age, gestational age, and clinical risk factors rather than as an isolated concentration. [1][8][22]

Treat the following as high-risk patterns: jaundice during the first 24 hours, gestational age 35–36 weeks, jaundice documented before discharge, prior sibling treated with phototherapy, bruising or cephalohematoma, and laboratory evidence or clinical concern for Rh or ABO incompatibility or G6PD deficiency. These findings increase the likelihood of severe hyperbilirubinemia and justify earlier repeat bilirubin testing and etiologic evaluation. [3]

Escalate immediately for clinical features of acute bilirubin encephalopathy or a serum bilirubin concentration above 340 micromol/L (approximately 19.9 mg/dL) in infants born at 37 weeks or later. A bilirubin rise exceeding 8.5 micromol/L per hour (approximately 0.5 mg/dL per hour) also identifies increased kernicterus risk and should prompt urgent reassessment for hemolysis, treatment adequacy, and exchange-level management. [17]
- If TSB reaches the exchange transfusion threshold, prepare exchange transfusion while continuing bilirubin-lowering treatment; perform the exchange unless TSB falls below the threshold during preparation. [17]
- Do not rely on visual jaundice assessment alone to exclude hazardous hyperbilirubinemia; obtain a measured TcB or TSB according to postnatal age and risk profile. [21]
- Recognize that kernicterus and severe hyperbilirubinemia can occur in otherwise healthy term or near-term infants, including infants without identified hemolytic disease. [3][5]

*High-risk findings that should accelerate serum bilirubin measurement, etiologic assessment, or escalation. [3][17][21]*

| Finding | Interpretation | Immediate next step |
| --- | --- | --- |
| Jaundice in first 24 hours | Pattern associated with severe hyperbilirubinemia and possible hemolysis. [3] | Obtain TSB and assess for blood-group incompatibility and hemolysis. [17] |
| TSB rise >8.5 micromol/L/h | Increased risk of kernicterus. [17] | Reassess urgently for ongoing bilirubin production and treatment need. [17] |
| TSB >340 micromol/L at ≥37 weeks | Increased kernicterus risk. [17] | Initiate urgent bilirubin-directed management and assess exchange need using the applicable threshold graph. [17] |
| Acute bilirubin encephalopathy features | Clinical high-risk state independent of the absolute bilirubin value. [17] | Urgently escalate care and prepare for exchange-level management. [17] |

## Use bilirubin surveillance to determine treatment and follow-up

Measurement timing must account for discharge timing and the expected bilirubin trajectory.

Measure either TcB or TSB between 24 and 72 hours of life and plot the result on the applicable predictive nomogram when immediate treatment is not indicated. Record the measured value and predictive zone in the discharge documentation and arrange follow-up according to the risk of progression to severe hyperbilirubinemia. [21]

Confirm TcB with TSB when the TcB is close to the phototherapy threshold. This avoids using a screening measure alone at the point where a small measurement difference can change whether intensive phototherapy is started. [8]

For an infant discharged before 24 hours of life, arrange clinical review within 24 hours by a clinician able to recognize neonatal hyperbilirubinemia, obtain TcB or TSB without delay, and refer for treatment when indicated. This timing rule applies regardless of day of the week. [21]
- Use TSB rather than TcB to guide phototherapy discontinuation, rebound assessment, exchange transfusion decisions, and readmission decisions. [1]
- Interpret predischarge bilirubin in the context of gestational age and evolving feeding and illness status; late-preterm infants require a lower threshold for repeat measurement because 35–36 week gestation is a recognized severe-hyperbilirubinemia risk factor. [3][21]
- Expect management thresholds to differ between older AAP guidance and the 2022 AAP guideline; the 2022 guideline increased phototherapy and exchange transfusion thresholds for infants born at 35 weeks or later. [22][23]

*Bilirubin surveillance actions by clinical setting. [1][8][21]*

| Setting | Measurement action | Decision consequence |
| --- | --- | --- |
| Routine birth hospitalization, 24–72 hours | Measure TcB or TSB and plot on a predictive nomogram if immediate therapy is not required. [21] | Use trajectory and risk zone to schedule follow-up. [21] |
| TcB near phototherapy threshold | Confirm with TSB. [8] | Use TSB for the phototherapy decision. [1][8] |
| Discharge before 24 hours | Arrange review within 24 hours with capacity for immediate TcB or TSB. [21] | Detect a rapidly rising bilirubin level before severe hyperbilirubinemia develops. [21] |
| During or after phototherapy | Follow TSB for treatment response and rebound assessment. [1] | Restart therapy if rebound requires it; rebound requiring repeat phototherapy occurs in about 5% overall and has been reported in up to 28% with hemolytic disease. [1] |

## Distinguish hemolysis from nonhemolytic bilirubin load and cholestasis

The workup should identify conditions that alter surveillance intensity, treatment response, and recurrence risk.

In significant hyperbilirubinemia, perform a full clinical examination and obtain serum bilirubin as part of formal assessment for underlying disease. Add infant and maternal blood group assessment, direct antiglobulin testing, and complete blood count to identify Rh or ABO incompatibility and anemia consistent with hemolysis. [17][3]

Test for G6PD deficiency in severe hyperbilirubinemia, particularly when the bilirubin trajectory is disproportionate to the apparent clinical findings or when hemolysis is suspected without a positive direct antiglobulin test. G6PD deficiency is a major risk factor for neonatal indirect hyperbilirubinemia and bilirubin-induced neuronal damage; affected infants may require intervention at lower TSB concentrations. [8][21]

A low hemoglobin concentration with reticulocytosis supports increased red-cell turnover; serial TSB behavior during intensive phototherapy is clinically useful because failure to achieve a sustained decline suggests ongoing bilirubin production or insufficient exposure. Phototherapy removes excess bilirubin but does not inhibit bilirubin production, which is particularly consequential in hemolytic disease. [1][8]

Measure direct as well as total bilirubin when prolonged jaundice or a cholestatic process is suspected. Early neonatal management usually targets unconjugated hyperbilirubinemia, whereas conjugated hyperbilirubinemia requires disease-specific evaluation rather than routine phototherapy escalation. [4]
- Rh or ABO incompatibility: use blood group testing and direct antiglobulin testing to support immune hemolysis. [3][17]
- G6PD deficiency: obtain an erythrocyte G6PD activity assay; severe hyperbilirubinemia warrants testing even when other hemolysis studies are unrevealing. [8][21]
- Bruising or cephalohematoma: treat as an increased bilirubin-load risk and repeat bilirubin measurement based on the measured trajectory. [3]
- Conjugated hyperbilirubinemia: pivot from the usual unconjugated-jaundice pathway to evaluation of the pathological cause. [4]

*Actionable etiologic patterns in neonatal jaundice. [1][3][4][8][17][21]*

| Pattern | Tests or findings | Management implication |
| --- | --- | --- |
| Immune hemolysis | Maternal/infant blood groups and direct antiglobulin test; CBC may show anemia. [17] | Monitor TSB closely because ongoing production can limit phototherapy response and increase escalation risk. [1] |
| G6PD-associated hyperbilirubinemia | Erythrocyte G6PD activity testing; consider in all severe cases. [8][21] | Use lower intervention thresholds where applicable and maintain close surveillance for bilirubin-induced injury. [21] |
| Increased bilirubin load from bruising or cephalohematoma | Physical examination identifies bruising or cephalohematoma. [3] | Increase surveillance because this is a recognized severe-hyperbilirubinemia risk factor. [3] |
| Predominantly unconjugated jaundice without identified hemolysis | TSB trajectory without evidence of Rh/ABO incompatibility or G6PD deficiency. [3][17] | Treat according to age-, gestation-, and risk-specific phototherapy thresholds. [1][22] |
| Conjugated hyperbilirubinemia or prolonged jaundice | Direct bilirubin elevation or prolonged course. [4] | Evaluate the underlying pathological cause; routine unconjugated-hyperbilirubinemia management is insufficient. [4] |

## Start phototherapy at the applicable threshold and prepare early for exchange transfusion

Treatment intensity should match the bilirubin trajectory and encephalopathy risk.

Initiate phototherapy when the TSB crosses the applicable threshold derived from postnatal age, gestational age, and neurotoxicity risk factors. The AAP 2022 guideline applies to infants born at 35 weeks or later and uses higher phototherapy and exchange transfusion thresholds than prior AAP guidance; use a current guideline-based threshold tool rather than legacy threshold figures. [22][23]

During intensive phototherapy, trend TSB to establish whether the concentration is falling adequately. Phototherapy converts bilirubin into excretable products and can provide a gradual, sustained bilirubin reduction in nonhemolytic hyperbilirubinemia, but it does not suppress bilirubin production and may fail to control ongoing hemolysis. [1][12]

For severe jaundice in nondehydrated infants receiving intensive phototherapy, additional oral or intravenous fluids have been associated with reduced progression to exchange transfusion. Use fluid supplementation as an adjunct to bilirubin-directed treatment rather than as a substitute for phototherapy or exchange preparation. [21]

Proceed to exchange transfusion when TSB reaches the age- and gestation-specific exchange threshold unless the level decreases below that threshold while preparation is underway. Exchange transfusion is reserved for severe hyperbilirubinemia because adverse events are common, particularly in preterm infants and those with concurrent neonatal morbidity; most reported events are laboratory abnormalities that are asymptomatic and treatable. [17][13]
- Use intensive phototherapy as first-line bilirubin-lowering therapy when the treatment threshold is met. [1][4]
- Continue active treatment while arranging exchange transfusion for exchange-level TSB or acute bilirubin encephalopathy. [17]
- Recheck TSB after phototherapy when rebound risk is clinically relevant, especially in hemolytic disease. Repeat phototherapy is required in about 5% of infants overall and has been reported in up to 28% of infants with hemolytic disease. [1]
- Do not assume a prior normal bilirubin result excludes subsequent severe disease; serial measurement is required when the trajectory, hemolysis risk, or early discharge raises concern. [3][21]

### Exchange transfusion tradeoff

Exchange transfusion can rapidly reduce hazardous bilirubin exposure but carries procedure-related morbidity. In a cohort of infants undergoing exchange transfusion, adverse events occurred more often in preterm infants and in infants with other neonatal morbidity; use this risk to reinforce early phototherapy and timely escalation, not to delay exchange when the exchange threshold or encephalopathy indication is met. [13][17]
- At 37 weeks or later, serum bilirubin greater than 340 micromol/L is a kernicterus risk marker, but exchange decisions should follow the applicable threshold graph and clinical status. [17]
- A bilirubin level above 425 micromol/L (approximately 24.9 mg/dL) has been used to define severe hyperbilirubinemia associated with high kernicterus risk. [3]

*Treatment selection for neonatal unconjugated hyperbilirubinemia. [1][4][13][17][21][22]*

| Clinical state | Action | Monitoring or escalation |
| --- | --- | --- |
| TSB below treatment threshold but at-risk trajectory | Arrange repeat TcB or TSB based on age, gestation, and risk profile. [21] | Accelerate testing for first-day jaundice, hemolysis risk, bruising, or late-preterm birth. [3] |
| TSB at phototherapy threshold | Start phototherapy using current age-, gestation-, and risk-specific thresholds. [1][22] | Trend TSB to confirm a sustained decline. [1] |
| Severe jaundice during intensive phototherapy | Consider additional oral or intravenous fluid supplementation in nondehydrated infants. [21] | Continue TSB surveillance and evaluate for hemolysis or inadequate response. [1][8] |
| TSB at exchange threshold or acute bilirubin encephalopathy | Prepare exchange transfusion and perform it unless TSB falls below threshold during preparation. [17] | Continue active bilirubin-lowering management while exchange is arranged. [17] |

## Discharge only with a documented bilirubin plan and timely reassessment

Follow-up failures are a major pathway to preventable severe hyperbilirubinemia.

Before discharge, document the TcB or TSB value, postnatal age at measurement, predictive risk designation when used, relevant risk factors, and the planned timing and location of reassessment. A predischarge TSB measured between 18 hours and 3 days can predict subsequent TSB above 300 micromol/L in direct antiglobulin test-negative term and late-preterm infants. [21]

Schedule earlier reassessment for infants with an elevated predictive-zone result, gestational age 35–36 weeks, jaundice before discharge, a sibling previously treated with phototherapy, bruising or cephalohematoma, or suspected hemolysis. The follow-up encounter must include capacity to measure TcB or TSB promptly and transfer the infant for treatment if indicated. [3][21]

After phototherapy, use TSB-based follow-up when rebound is a concern. Hemolytic disease materially increases rebound risk; a recurrent rise requiring repeat phototherapy has been reported in as many as 28% of affected infants. [1]
- Provide the predischarge bilirubin result and risk assessment to the family and receiving clinician. [21]
- For discharge before 24 hours, require reassessment within 24 hours. [21]
- Use readmission for phototherapy when the postdischarge TSB reaches the applicable treatment threshold; jaundice remains a leading cause of newborn hospital readmission. [1][3]

*Disposition checklist for infants with neonatal jaundice. [1][3][21]*

| Before discharge | Required documentation or action | Reason |
| --- | --- | --- |
| Bilirubin status | Record TcB or TSB, timing, and predictive risk designation when immediate treatment is not needed. [21] | Estimates likelihood of progression after discharge. [21] |
| Risk-factor review | Identify first-day jaundice, 35–36 week gestation, sibling phototherapy history, bruising/cephalohematoma, and hemolysis risk. [3] | Determines need for earlier repeat bilirubin testing. [3][21] |
| Follow-up logistics | Confirm access to prompt TcB or TSB testing and treatment referral. [21] | Prevents delay when bilirubin rises after discharge. [21] |
| Post-phototherapy plan | Use TSB follow-up when rebound risk is clinically important, especially with hemolytic disease. [1] | Identifies infants needing restarted phototherapy. [1] |

## References
1. Stannsoporfin for Neonatal Hyperbilirubinemia — www.fda.gov — https://www.fda.gov/media/169881/download
2. Universal Transcutaneous Bilirubin Screening in a ... — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2843732
3. Incidence and causes of severe neonatal hyperbilirubinemia in Canada — bmjpaedsopen.bmj.com — https://bmjpaedsopen.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiY21haiI7czo1OiJyZXNpZCI7czo5OiIxNzUvNi81ODciO3M6NDoiYXRvbSI7czoyMzoiL2JtanBvLzEvMS9lMDAwMTA1LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==
4. Neonatal jaundice - Symptoms, diagnosis and treatment | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/672
5. Neonatal hyperbilirubinaemia: a global perspective — www.thelancet.com — https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(18)30139-1/abstract
6. Outcomes among Newborns with Total Serum Bilirubin ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa054244
7. Neonatal Hyperbilirubinemia — What Are the Risks? — www.nejm.org — https://www.nejm.org/doi/abs/10.1056/nejme068053
8. Glucose-6-phosphate dehydrogenase deficiency and neonatal indirect hyperbilirubinemia: a retrospective cohort study among 40,305 consecutively born babies | Journal of Perinatology — www.nature.com — https://www.nature.com/articles/s41372-024-01927-1
9. Exchange transfusion safety and outcomes in neonatal hyperbilirubinemia | Journal of Perinatology — www.nature.com — https://www.nature.com/articles/s41372-020-0642-0
10. Neonatal Jaundice and Hyperbilirubinemia Management | Nature Research Intelligence — www.nature.com — https://www.nature.com/research-intelligence/nri-topic-summaries/neonatal-jaundice-and-hyperbilirubinemia-management-micro-12137
11. Is it Accurate to Separate Glucose-6-Phosphate Dehydrogenase Activity in Neonatal Hyperbilirubinemia as Deficient and Normal? - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1875957213002209
12. Comparison of the effectiveness of phototherapy and exchange transfusion in the management of nonhemolytic neonatal hyperbilirubinemia - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0022347675808377
13. Adverse events associated with neonatal exchange transfusion in the 1990s - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S002234760400099X
14. Hyperbilirubinemia - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/nursing-and-health-professions/hyperbilirubinemia
15. Neonatal jaundice incidence, risk factors and outcomes in ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.17865
16. Relation between neonatal jaundice and oncostatin M, ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/pdf/10.1080/00016340802468332
17. Jaundice in newborn babies under 28 days | Guidance — www.nice.org.uk — https://www.nice.org.uk/guidance/cg98/chapter/Recommendations
18. Transcutaneous Bilirubin Accuracy Before, During, and ... — pediatrics.aappublications.org — https://pediatrics.aappublications.org/pediatrics/article/doi/10.1542/peds.2023-062335/195647/Transcutaneous-Bilirubin-Accuracy-Before-During
19. American Academy of Pediatrics — www.aappublications.org — https://www.aappublications.org
20. The Utility of HIDA Scans for the Evaluation of Cholestasis ... — pediatrics.aappublications.org — https://pediatrics.aappublications.org/content/142/1_meetingabstract/214
21. Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks’ gestation) – Summary - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2528724
22. Bilirubin Measurement and Phototherapy Use After the AAP 2022 Newborn Hyperbilirubinemia Guideline | Pediatrics | American Academy of Pediatrics — publications.aap.org — https://publications.aap.org/pediatrics/article/153/4/e2023063323/196871/Bilirubin-Measurement-and-Phototherapy-Use-After
23. Implementing Higher Phototherapy Thresholds for Jaundice in Healthy Infants 35 Plus Weeks | Hospital Pediatrics | American Academy of Pediatrics — publications.aap.org — https://publications.aap.org/hospitalpediatrics/article/13/9/857/193753/Implementing-Higher-Phototherapy-Thresholds-for
24. NEWBORN - IRIS — iris.who.int — https://iris.who.int/bitstreams/1bc93a8d-b367-4ee0-9581-f1a00965894e/download

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.